$0.16
-0.11(-40.72%)
Mkt Cap $523.7K
$0.15
$0.93
52-Week Range
At a Glance
AI-generatedAvenue Therapeutics narrowed its net loss by 74.8% to -$2.9M from -$11.7M, driven by AJ201 return to AnnJi and Baergic divestiture that reduced development costs, while operating cash burn improved to -$1.8M from -$9.0M amid financing needs.
$523.7K
Market Cap
$1M
Revenue
-$4M
Net Income
Employees2
Fundamentals
How The Business Makes Money
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001644963
ISINUS05360L3042
CUSIP05360L205
Phone781 652 4500
Address1140 Avenue of the America, New York City, NY, 10036, US
SEC EDGAR